RxDoctor Payments Data

David Marks, MD

Psychiatry · Chapel Hill, NCNPI 1760499933

Payments from drug & device makers

$2,043in general payments, 2019–2025

Across 113 payments — averaging $18.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$500
  • AbbVie$294
  • Teva Pharmaceuticals USA, Inc.$216
  • Johnson & Johnson$183
  • Vanda Pharmaceuticals Inc.$173
  • Pfizer$117
  • plus $560 from 14 others

What the payments were for

  • Food & beverage$2,043100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,043 in reported general payments places this provider in the 80th percentile of 1,108 psychiatry providers in North Carolina.

See all psychiatry providers in North Carolina

Medicare billing

Part B allowed, 2024
$83,623
Medicare patients
156
Services billed
834

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxycontinOxycodone Hcl141$166,954
Xtampza ErOxycodone Myristate80$91,984
NucyntaTapentadol Hcl18$26,545
Oxycodone Hcl550$21,292
Morphine Sulfate ErMorphine Sulfate263$13,934
LinzessLinaclotide26$13,674
Buprenorphine35$11,796
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen214$10,618
MovantikNaloxegol Oxalate25$10,047
Hydromorphone ErHydromorphone Hcl24$9,531
BelsomraSuvorexant20$8,663
TrintellixVortioxetine Hydrobromide16$8,566
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen214$7,008
Fentanyl71$5,846
Hydromorphone Hcl233$5,680

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er, Nucynta$58$118,52998 claims
AbbVieLinzess, Savella$294$18,15138 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$19$8,56616 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,108 psychiatry providers in North Carolina.

Other psychiatry in Chapel Hill

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →